JPRN-jRCT2051200050已完成3 期
An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman's disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT Compliant)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients may be included if all of the following criteria are met:
- •(1) Patients who have completed 16-week treatment with investigational drug treatment in the preceding trial
- •(2) Patients who have received a thorough explanation of the contents of explanatory documents and other matters concerning clinical trials understood the contents thereof and provided written consent based on their free will to participate in this trial. In case the patient is under 20 years of age at the time of obtaining the consent, the patient has obtained written consent to participate in the clinical trial from the proxy and written consent to participate in the clinical trial from the patient himself/herself.
排除标准
- •Patients with any one of the following will be excluded
- •(1) Patients with an Eastern Cooperative Oncology Group Performance Status of 4.
- •(2) Patients (males and females of childbearing potential) who are unable to use an appropriate method of contraception during the period of study drug administration and 12 weeks after the last dose of study drug
- •(3) Female patients who are breastfeeding or pregnant
- •(4) Patients with complications of serious diseases that are deemed unsuitable for the clinical trial by the investigator or sub-investigator
- •(5) Patients whose condition in a prior study is deemed unsuitable for continued treatment by the investigator or subinvestigator
- •(6) Other patients who deemed inappropriate by the investigator or sub-investigator
研究者
相似试验
进行中（未招募）
1 期
on-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related OvergrowthEUCTR2014-005320-10-FRCHU de DIJO
进行中（未招募）
1 期
Sirolimus treatment for segmental overgrowthEUCTR2014-000484-41-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge11
已完成
2 期
An open label phase II study of Sirolimus in patients with segmental overgrowth syndromeSEGMENTAL OVERGROWTH SYNDROMEQ85.8Q87.8Q87.3Other phakomatoses, not elsewhere classifiedOther specified congenital malformation syndromes, not elsewhere classifiedCongenital malformation syndromes involving early overgrowthDRKS00010085niversitätsklinikum Freiburg18
进行中（未招募）
1 期
Studie zu Sirolimus bei Patienten mit ÜberwuchssyndromSegmental overgrowth syndromeEUCTR2015-005416-15-DEMedical Center - University of Freiburg18
进行中（未招募）
1 期
A study investigating long-term treatment with spesolimab in people with a skin disease called hidradenitis suppurativa who completed a previous clinical trial.MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersHidradenitis SuppurativaEUCTR2020-005587-55-NOBoehringer Ingelheim Norway KS45